Skip to content
Peptide.Guide
PreclinicalCognitiveOralDailyHGF/c-Met signaling has cancer-promoting potentialPartial data

Dihexa

PNB-0408

Angiotensin IV analog with potent synaptogenic activity in preclinical models; potency much higher than BDNF in some assays.

§ 01   Overview

Overview

Angiotensin IV analog with potent synaptogenic activity in preclinical models; potency much higher than BDNF in some assays.

Rodent data only. No human trials.

§ 02   Mechanism

Mechanism of action

Dihexa binds and activates HGF/c-Met signaling, promoting dendritic spine formation and synaptogenesis in the hippocampus.

  • 01Strong synaptogenesis in rodent models
  • 02Proposed nootropic use

§ 03   Dosing

Dosing protocol

Standard Protocol

Dose Range
8 – 20 mg (research)
Route
Oral
Frequency
Daily
Cycle
Short cycles

§ 04   Evidence

Evidence & research

Preclinical

Rodent data only. No human trials.

FDA Status

Not FDA-approved.

§ 06   News

In the news

2 articles from the last 12 months · updates hourly

§ 07   Sourcing

Sourcing & supply

Regulatory status

Research-only, no commercial channel

No commercial channel exists. Available only as a research reagent from RUO suppliers. Use in humans is not established.

No suppliers in our directory currently stock this compound. For investigational or research-only compounds, legitimate channels may not exist outside clinical trials.

Browse full supplier directory

§ 09   Safety

Safety & side effects

Side effects

  • 01Unknown in humans

Contraindications

  • 01Active or prior cancer

This site is for educational and research purposes only. It does not constitute medical advice. Always consult a qualified healthcare provider before using any peptide or supplement.